API

Therapeutic areas and Global Demand Data released for upcoming FY24-25 launches

Credit profile of ICRA’s sample set companies to remain comfortable with Total Debt/OPBDITA of 1.2 times in FY2025

Kotak Alt invests Rs 1445 Cr for the acquisition, aims to strengthen Matirx’s API business by third-party sales and selectively…

To manufacture and supply API in the therapeutic area of urinary anti-spasmodic

Equipped with Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs 200…

The quarter saw 26 deals totalling $2.7 billion, with a 32 per cent decline in deal volumes compared to Q3 2022

Ind-Swift reported a consolidated revenue of Rs 1,207 crores and consolidated EBITDA of Rs 256 crores in FY23

Consolidated profit rose to Rs 1.24 billion ($15.22 million) for the three months ended 31st December, from Rs 1.01 billion a year…

The US Food and Drug Administration (FDA) had inspected the Mandideep Unit-1 facility in Madhya Pradesh from 14th November, 2022,…

While formulation generics flounders a bit, the data show that the Indian API industry has done better, with a five-year revenue…